Dergiler / Turkish Thoracic Journal / 2020 / Cilt: 21 - Sayı: 6

Imatinib Treatment for Bleomycin-Induced Pulmonary Toxicity

Sayfa
457–460
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The patient, who is still under follow-up without any therapy until now, demonstrated that in cases of bleomycin-induced pulmonary toxicity that is unresponsive to corticosteroids, addition of imatinib to the treatment can be an alternative option.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The basic treatment for bleomycin-induced pulmonary toxicity is corticosteroids.
📊
Temel Bulgular & Veri:We present a case of a 51-year-old man, diagnosed with seminoma, who was receiving a combination treatment of bleomycin, etoposide, and cisplatin when admitted to the hospital with progressive cough and exercise-induced dyspnea.
💡
Sonuç & Katkı:The patient, who is still under follow-up without any therapy until now, demonstrated that in cases of bleomycin-induced pulmonary toxicity that is unresponsive to corticosteroids, addition of imatinib to the treatment can be an alternative option.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

The basic treatment for bleomycin-induced pulmonary toxicity is corticosteroids. However, unresponsiveness to corticosteroid treatment can be observed in some cases. We present a case of a 51-year-old man, diagnosed with seminoma, who was receiving a combination treatment of bleomycin, etoposide, and cisplatin when admitted to the hospital with progressive cough and exercise-induced dyspnea. The patient’s computed thorax tomography imaging showed bilateral consolidation of lungs, bronchoalveolar lavage (BAL) showed neutrophilia, and transbronchial biopsy showed fibroblastic proliferation. The sputum and BAL cultures were all sterile, and the patient was treated with methylprednisolone for the diagnosis of acute interstitial pneumonia. However, despite the corticosteroid treatment, patient suffered a respiratory failure. On the sixteenth day, imatinib 300 mg/day was added to the corticosteroid treatment. The result of the combination therapy was successful; therefore, corticosteroid and imatinib were stopped at the fifth and ninth month of the combination treatment, respectively. The patient, who is still under follow-up without any therapy until now, demonstrated that in cases of bleomycin-induced pulmonary toxicity that is unresponsive to corticosteroids, addition of imatinib to the treatment can be an alternative option.

🔖

Bu Makaleye Atıf Yap

AYKAÇ, N., TECİMER, C. (2020). Imatinib Treatment for Bleomycin-Induced Pulmonary Toxicity. Turkish Thoracic Journal, Cilt: 21 - Sayı: 6, 457–460. https://ajindex.com/articles/179205

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. O’Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003;14:91-6. [CrossRef] 2. Sleifer S: Bleomycin-induced pneumonia. Chest 2001;120:617-24. [CrossRef] 3. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005;23:7614-20. [CrossRef] 4. Reinert T, Baldotto CSDR, Nunes FAP, et al. Bleomycin-induced lung injury. J Cancer Res 2013; Article ID: 480608, 9 pages. [CrossRef] 5. Sleijfer S, van der Mark TW, Schraffordt Koops H, et al. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur J Cancer 1996; 32A: 550. [CrossRef] 6. Haugnes HS, Aass N, Fosså SD, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009;27:2779. [CrossRef] 7. Silva CI, Müller NL. Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. Semin Ultrasound CT MR 2006;27:111. [CrossRef] 8. White DA, Stover DE. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. Chest 1984;86:723. [CrossRef] 9. Delanoy N, Pécuchet N, Fabre E, et al. Bleomycin-induced pneumonitis in the treatment of ovarian sex cord-stromal tumors: a systematic review and meta-analysis. Int J Gynecol Cancer 2015;25:1593-8. [CrossRef] 10. Kral JB, Kuttke M, Schrottmaier WC, et al. Sustained PI3K activation exacerbates BLM-induced lung fibrosis via activation of proinflammatory and pro-fibrotic pathways. Sci Rep 2016;6:23034. [CrossRef] 11. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16. [CrossRef] 12. Rhee CK1, Lee SH, Yoon HK, et al. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration 2011;82(3):273-8. [CrossRef] 13. Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, et al. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin’s lymphoma: hope for severe chemotherapy-induced toxicity? J Clin Oncol 2011;29:691-3. [CrossRef] 14. Banakh I, Lam A, Tiruvoipati R, et al. Imatinib for bleomycin induced pulmonary toxicity: A case report and evidence-base review. Clin Case Rep 2016;4:486